Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.46), $0.45 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $35 million versus the consensus estimate of $22.38 million.

Guidance:

Raises FY2017 guidance to $125-130 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
• Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance